BACTERIOSTATIC ANTIBIOTICS MARKET ANALYSIS

Bacteriostatic Antibiotics MarketSize and Trends

Global bacteriostatic antibiotics market is expected to witness a significant growth over the forecast period, owing to recent approval and launch of novel bacteriostatic antibiotics products in the market.

For instance, in September 2018, Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company dedicated to development, manufacturing, and commercialization of novel antibiotics for treat life-threatening multidrug-resistant (MDR) infections received European Commission (EC) marketing authorization for its novel bacteriostatic antibiotic namely XERAVA (eravacycline) injection, which is indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults in the European Union. XERAVA (Eravacycline) is a fluorocycline antibacterial within the tetracycline class of antibacterial drugs, it is bacteriostatic against gram-positive bacteria (e.g., Staphylococcus aureus and Enterococcus faecalis)

Furthermore, high prevalence of bacterial and infectious disease is expected to propel demand for bacteriostatic antibiotics, in turn driving global bacteriostatic antibiotics market growth.

For instance, according to the data published by Centers of Disease Control and Prevention (CDC), in 2016, an estimated 9,272 people suffered from tuberculosis, 53,850 from salmonella, and 36,429 from Lyme disease in the U.S.